Frequently Asked Questions

The COREVENA Model is COREVENA’s technology transfer approach for orthopedic implant manufacturing. It combines turnkey facility setup, production-ready know-how transfer, customized design solutions developed through reverse engineering, and OEM supply integration in one structured model.

Yes. COREVENA sets up the facility on-site and transfers the complete operational know-how — including SOPs, training, and quality systems — so the facility is ready to operate from day one. The COREVENA Technology Transfer Model is designed for investors without prior manufacturing experience.

The COREVENA model is built on direct hands-on experience in orthopedic implant manufacturing, design, technology transfer, and supply chain execution. The model is built on real project experience, not theory.

Once the technology transfer is completed, the investor is not tied to COREVENA for ongoing operations. The investor may continue independently, or may continue working with COREVENA on facility expansion, new product integration, quality system development, reverse-engineering-based design solutions, capacity increases, other service modules, and OEM supply continuity. Any continued cooperation after launch depends on the investor’s decision and the agreed scope.

Returns depend on product scope, market size, and pricing — but the orthopedic implant manufacturing model is structurally high-margin. Local production eliminates import costs and enables competitive pricing in tender-driven markets, which typically drives strong EBITDA margins and a payback period of 3 to 5 years under realistic assumptions, , including a 2-year start-up phase.

Investment size varies by product scope, facility conditions, and phasing strategy. As part of the project study, COREVENA provides a detailed investment model covering technology transfer CAPEX, facility-related assumptions, and implementation phasing — so you enter the project with clear visibility on the required investment before committing.

The commercial structure is defined based on the selected project scope, deliverables, product portfolio, and phasing. The full COREVENA Model combines turnkey facility setup, production-ready know-how transfer, customized design solutions developed through reverse engineering, and OEM supply integration in one integrated package. Customers may also select only one or several of these modules and receive a project-specific commercial proposal accordingly.

Yes. Detailed financial feasibility reports are prepared upon request — for internal evaluation, investor discussions, or bank submissions — and if the project proceeds, the related fee is credited against the technology transfer payment.

COREVENA’s core focus is orthopedic implants and matching surgical instrument sets. Depending on the project scope, the model can be structured to cover all major orthopedic categories — including arthroplasty, arthroscopy, trauma, and spinal systems — or only selected categories.

Yes. In addition to orthopedic implants and matching surgical instrument sets, the same facility and quality infrastructure can also be used for selected adjacent medical device categories — such as dental implants, cardiovascular implants, and hemostatic agents — depending on project scope and feasibility.

Yes. COREVENA commits contractually to preserving compatibility with the customer’s existing surgical instrument sets. Through reverse engineering, a customized product design is developed for the customer while maintaining instrument-set compatibility.

The product designs developed within the project belong to the customer. Their rights and confidentiality are protected under the project agreements, and they are not shared with third parties without the customer’s prior written approval.

The process starts with a direct discussion with the customer to understand market needs, product priorities, facility conditions, and project expectations. Based on this, COREVENA defines the technology transfer scope and prepares a customized preliminary project outline and proposal.

The production line can be ready within 6 to 12 months, together with the customized implant design package. Timeline varies by product scope and facility conditions, but COREVENA’s structured setup model is designed to keep the project on schedule.

The facility setup and product design development process, including validation, can typically take 6 to 12 months. Beyond that, commercialization depends on product registration procedures, requirements within the target country’s healthcare system, and the regulatory and administrative timeline in the customer’s country.

Yes. The facility is designed for phased growth from the start — additional product lines, higher capacity, or new device categories can be added without rebuilding the core infrastructure.

Regulatory registration is the investor’s responsibility as the legal manufacturer. COREVENA delivers the technical documentation package and establishes the QMS structure required for registration. CE and ISO certification consulting is available as an optional service scope.

Under the full COREVENA Model, quality assurance and product responsibility are defined contractually across the full project scope — including raw materials, semi-finished components, design-related inputs, know-how transfer, and the production setup delivered by COREVENA. If the customer selects a narrower technology transfer scope, the responsibility and quality assurance framework is limited accordingly. For example, if the customer chooses only the design solutions package and excludes factory setup, know-how transfer, and OEM supply integration, COREVENA’s responsibility is limited to the design scope only.

COREVENA works in line with the customer’s sourcing preferences. Customers may source selected components independently, or through COREVENA if request. Where needed, COREVENA supply components through its own supplier network, under COREVENA’s own supply responsibility.

COREVENA uses a multi-sourcing strategy with a broad qualified supplier network, reducing dependence on any single source. For clients who require it, long-term supply commitments of up to 10 years can be structured to support business continuity planning.